Denis Mulleman

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Topics

Rheumatoid Arthritis

Top Venues

Annals of the rheumatic diseases

Rheumatology international

This page only lists publications with an associated author ORCID identifier.

Publications

Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
David Moulin, Marie Millard, Mahdia Taïeb, Chloé Michaudel, Anne Aucouturier, Antoine Lefèvre, Luis G Bermúdez-Humarán, Philippe Langella, Youssouf Sereme, Kristell Wanherdrick, Preeti Gautam, Xavier Mariette, Philippe Dieude, Jacques-Eric Gottenberg, Jean-Yves Jouzeau, David Skurnik, Patrick Emond, Denis Mulleman, Jérémie Sellam, Harry Sokol
Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis. Annals of the rheumatic diseases (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Johan Law-Wan, Marc-Antoine Sparfel, Sophie Derolez, Nicolas Azzopardi, Philippe Goupille, Jacqueline Detert, Denis Mulleman, Theodora Bejan-Angoulvant
Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD open 7 (3) (2022)
Pauline Richebé, Guillaume Coiffier, Pascal Guggenbuhl, Denis Mulleman, Marion Couderc, Emanuelle Dernis, Valentine Deprez, Carine Salliot, Saik Urien, Rachel Brault, Adeline Ruyssen-Witrand, Emmanuel Hoppe, Emmanuel Chatelus, Christian Hubert Roux, Sébastien Ottaviani, Marie Baufrere, Alexia Michaut, Loic Pauvele, Christelle Darrieutort-Laffite, Daniel Wendling, Pascal Coquerelle, Géraldine Bart, Elisabeth Gervais, Vincent Goeb, Marc Ardizzone, Edouard Pertuiset, Sophie Derolez, Jean Marc Ziza, René-Marc Flipo, Sophie Godot, Raphaèle Seror
Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017. Annals of the rheumatic diseases (2022)
Charlotte Lm Krieckaert, Astrid van Tubergen, Johanna Elin Gehin, Borja Hernández-Breijo, Guillaume Le Mélédo, Alejandro Balsa, Peter Böhm, Sasa Cucnik, Ori Elkayam, Guro L Goll, Femke Hooijberg, Meghna Jani, Patrick Dw Kiely, Neil McCarthy, Denis Mulleman, Victoria Navarro-Compán, Katherine Payne, Martin E Perry, Chamaida Plasencia-Rodriguez, Simon R Stones, Silje Watterdal Syversen, Annick de Vries, Katherine M Ward, Gertjan Wolbink, John Dudley Isaacs
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the rheumatic diseases (2022)
Charlotte Lm Krieckaert, Borja Hernández-Breijo, Johanna Elin Gehin, Guillaume le Mélédo, Alejandro Balsa, Meghna Jani, Denis Mulleman, Victoria Navarro-Compan, Gertjan Wolbink, John Isaac, Astrid van Tubergen
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD open 8 (2) (2022)
David Ternant, Olivier Le Tilly, Laurence Picon, Driffa Moussata, Christophe Passot, Theodora Bejan-Angoulvant, Céline Desvignes, Denis Mulleman, Philippe Goupille, Gilles Paintaud
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model. Pharmaceutics 13 (11) (2021)
Germano Vera Cruz, Emilie Bucourt, Christian Réveillère, Virginie Martaillé, Isabelle Joncker-Vannier, Philippe Goupille, Denis Mulleman, Robert Courtois
Machine learning reveals the most important psychological and social variables predicting the differential diagnosis of rheumatic and musculoskeletal diseases. Rheumatology international (2021)
Emilie Ducourau, Theo Rispens, Marine Samain, Emmanuelle Dernis, Fabienne Le Guilchard, Lucia Andras, Aleth Perdriger, Eric Lespessailles, Antoine Martin, Grégoire Cormier, Thomas Armingeat, Valérie Devauchelle-Pensec, Elisabeth Gervais, Benoit Le Goff, Annick de Vries, Eric Piver, Gilles Paintaud, Céline Desvignes, David Ternant, Hervé Watier, Philippe Goupille, Denis Mulleman
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD open 6 (1) (2020)